Incyte公司 (INCY)
收市後：
| 前收市價 | 67.04 |
| 開市 | 67.37 |
| 買盤 | 67.47 x 200 |
| 賣出價 | 67.52 x 400 |
| 今日波幅 | 66.45 - 67.55 |
| 52 週波幅 | 50.27 - 70.36 |
| 成交量 | |
| 平均成交量 | 2,054,876 |
| 市值 | 12.998十億 |
| Beta 值 (5 年，每月) | 0.74 |
| 市盈率 (最近 12 個月) | 164.61 |
| 每股盈利 (最近 12 個月) | 0.41 |
| 業績公佈日 | 2024年10月29日 - 2024年11月04日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 74.08 |
ZacksIncyte Gains 12.7% Year to Date: How Should You Play the Stock?
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
BenzingaIncyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in 2028. Jakafi is Incyte’s top-selling drug. It is indicated for polycythemia vera in adults, intermediate or high-risk myelofibrosis in adults, and steroid-refractory acute graft versus host disease in adult and pediatric patients. In second quarter 2024, the drug generated sales of $705.9 million, +3% year-over-year, driven by a 9% increase in paid demand. The analyst downg
Investor's Business DailyIntel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
Dow Jones tech giant Intel led the S&P 500 Monday, and kept running late. Apple chipmakers Qorvo and Skyworks sold off on iPhone 16 concerns.
